In a patient with severe aortic stenosis (aortic valve area 0.4 cm², peak aortic valve inflow velocity 5.3 m/s), should we proceed with surgical aortic valve replacement, transcatheter aortic valve replacement, or attempt valve repair?

Valve Replacement is Indicated—Not Repair

Aortic valve repair is not a viable option for severe calcific aortic stenosis; you must proceed with either SAVR or TAVR based on surgical risk stratification and patient-specific factors. The CTVS suggestion of valve repair is inappropriate for this pathology—repair is reserved for aortic regurgitation or specific anatomic scenarios, not stenosis 1, 2, 3.

Your Patient Has Very Severe Aortic Stenosis

With an aortic valve area of 0.4 cm² and peak velocity of 5.3 m/s, this patient meets criteria for very severe aortic stenosis (velocity ≥5 m/s) 4. This is a Class I indication for intervention regardless of symptoms if the patient is symptomatic, or even if asymptomatic with certain high-risk features 1, 2, 3.

Decision Algorithm: SAVR vs TAVR

Step 1: Calculate Surgical Risk

Determine the STS-PROM score:

• Low risk: STS <4% → SAVR is recommended as first-line 5, 2, 3
• Intermediate risk: STS 4-8% → Either SAVR or TAVR is reasonable; choice depends on additional factors 5, 1
• High risk: STS >8% → TAVR is favored 1, 2
• Prohibitive risk: ≥50% mortality/morbidity at 30 days → TAVR is indicated 1

Step 2: Assess Additional Risk Factors Not Captured by STS Score

Even if STS score suggests low-intermediate risk, consider:

• Frailty (use validated frailty assessment)
• Porcelain aorta (on CT imaging)
• Prior chest radiation
• Severe hepatic disease (Child-Pugh B/C)
• Severe pulmonary disease (FEV1 <1L, DLCO <40%)
• Hostile chest (prior cardiac surgery with patent grafts)

If any of these are present, TAVR becomes the preferred option even with lower STS scores 5, 1, 5, 2.

Step 3: Consider Patient Age and Life Expectancy

• Age <65-70 years with low surgical risk → SAVR strongly preferred for superior long-term durability 2, 6
• Age >75-80 years → TAVR is increasingly favored due to faster recovery and similar outcomes 7, 8, 9
• Life expectancy <1 year → Neither intervention is appropriate; consider palliative balloon valvuloplasty 1, 4

Step 4: Evaluate Anatomic Suitability

For TAVR:

• Adequate vascular access (femoral/iliac arteries ≥5-6mm diameter)
• Appropriate annulus size (18-29mm for most devices)
• Sufficient distance from annulus to coronary ostia (>10-12mm)
• Absence of severe bicuspid anatomy (relative contraindication) 1, 3

For SAVR:

• Need for concomitant procedures (CABG, ascending aorta surgery, other valve surgery) → SAVR mandatory 1, 2, 3

Specific Recommendation Based on Risk Profile

If Low Surgical Risk (STS <4%, Age <70-75, No Frailty):

Proceed with SAVR 2, 3. This provides:

• Superior long-term durability (proven >20 years)
• Lower rates of paravalvular regurgitation
• Lower pacemaker requirement
• Better hemodynamics (lower gradients, larger effective orifice area) 10, 11

If Intermediate Risk (STS 4-8%) or Age 70-80:

Either SAVR or TAVR is appropriate 5, 2, 9. Favor TAVR if:

• Transfemoral access is feasible
• Patient prefers faster recovery (hospital stay 1-2 days vs 8-9 days) 7, 10
• Frailty is present

Favor SAVR if:

• Patient is younger end of spectrum (<75 years)
• Concomitant cardiac disease requiring surgery
• Bicuspid valve anatomy

If High/Prohibitive Risk (STS >8%, Severe Frailty, or Prohibitive Factors):

Proceed with TAVR 1, 2. TAVR demonstrates:

• Lower 30-day mortality in high-risk patients (3-5% vs 6-7% with SAVR) 12
• Reduced major bleeding, acute kidney injury, and atrial fibrillation 10, 9
• Faster recovery and shorter hospitalization 7

Critical Pitfalls to Avoid

1. Do not attempt valve repair for calcific aortic stenosis—this is anatomically impossible and represents a fundamental misunderstanding of the pathology
2. Do not delay intervention with very severe AS (velocity 5.3 m/s)—this carries high risk of sudden death even if asymptomatic 4
3. Do not use STS score alone—it underestimates risk in elderly patients and doesn't capture frailty, cognitive dysfunction, or liver disease 5
4. Do not proceed without CT angiography—this is mandatory for TAVR planning and increasingly standard for all AS patients 5, 7
5. Do not choose TAVR in young patients (<65 years) with low surgical risk without compelling contraindications to surgery—long-term durability data beyond 10 years are lacking 6, 13

Mandatory Next Steps

1. Multidisciplinary Heart Team evaluation involving interventional cardiology and cardiac surgery 5, 2, 3
2. Cardiac CT angiography to assess:
   • Annular dimensions
   • Coronary anatomy and height
   • Vascular access suitability
   • Aortic root anatomy
3. Calculate formal STS-PROM score using all required variables
4. Assess frailty using validated tools (gait speed, grip strength, mini-nutritional assessment) 5
5. Confirm symptom status—even "asymptomatic" patients with very severe AS warrant intervention 4, 13

The choice between SAVR and TAVR should be made by the Heart Team within 1-2 weeks of evaluation, not deferred 5, 13. With a peak velocity of 5.3 m/s, this patient is at high risk for rapid decompensation and requires urgent definitive treatment.